



Miami Investigator Meeting
Closing Presentation
Ben Zimmer, Priovant CEO

Priovant: How We Strive To Be Distinctive

- Focused exclusively on rarer autoimmune disease with highest morbidity mortality
 - At most pharma companies (including many doing work in myositis), these indications are of secondary business priority – at Priovant they are our raison d'être
- Even among rarer autoimmune disease, we are particularly focused on DM as our lead indication for brepocitinib
 - Strive to work with you as true members/partners of the myositis community, not just “corporate sponsors”
- Our approach to the VALOR study is very hands on – every member of our small company is deeply passionate about making this study a success and willing to work tirelessly to make it so
 - Site teams are part of the Priovant team; we hope that you share our passion and dedication
- We view the relationships we are building with you now as laying a long-term foundation that will go beyond this study

What I Ask Of You Coming Out Of This Meeting

- 1. Make an effort to enroll an additional 1-2 qualified/appropriate subjects (or more!) this Spring**
- 2. In executing/conducting the study, strive not just for competence but for excellence**
 - For each subject enrolled in the study, commit yourself and your team to the level of time commitment and detail-orientation needed to generate the best possible data
 - Four particular themes
 - Appropriate patients
 - High-quality assessments
 - Steroid taper
 - Rescue medication/prohibited medications

The logo for Prioivant Therapeutics features the word "prioivant" in a dark blue, lowercase, sans-serif font. A stylized graphic of a double-strand DNA molecule, consisting of two blue spheres connected by a thin blue line, is positioned over the "io" in "prioivant". Below the main text, the word "therapeutics" is written in a smaller, light blue, lowercase, sans-serif font, with each letter spaced out.

prioivant
therapeutics